Authorities approve the application of NovaMedica for a new production facility

Print 26 December 2017
GMP News

NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the approval of the Inter-Agency Commission for conclusion of Special Investment Contract (SPIC) under the investment project aimed at establishing a pharmaceutical plant for sterile injectable drugs in the Kaluga region.

The portfolio of medicines agreed with the Inter-Agency Commission includes vital and essential drugs transferred to Novamedica under the partnership with Pfizer, as well as the results of proprietary R&D conducted by NovaMedica. SPIC provides for expansion of this list following the development of proprietary R&D conducted by NovaMedica in agreement with the Inter-Agency Commission. The company plans to produce more than 40 advanced and effective drugs sought after by Russian patients.

“Building a high-tech pharmaceutical production facility from scratch in full compliance with international quality standards will allow us to provide effective medicines to Russian patients and open the opportunities for exporting our products. This SPIC is very important to us. We would like to thank for their support the Ministry of Industry and Trade of the Russian Federation and the administration of the Kaluga region, where we will build our plant, and also Pfizer, our strategic partner who gives us valuable knowledge and technology for manufacturing the advanced and highly-demanded drugs,” said Alexander Kuzin, the General Director of NovaMedica.

Return